DB:GTN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions.


Snowflake Analysis

Good value with adequate balance sheet.


Similar Companies

Share Price & News

How has Getinge's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GTN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.8%

GTN

-0.8%

DE Medical Equipment

-3.6%

DE Market


1 Year Return

55.0%

GTN

21.7%

DE Medical Equipment

3.7%

DE Market

Return vs Industry: GTN exceeded the German Medical Equipment industry which returned 22.5% over the past year.

Return vs Market: GTN exceeded the German Market which returned 3.8% over the past year.


Shareholder returns

GTNIndustryMarket
7 Day0.8%-0.8%-3.6%
30 Day19.6%3.5%-2.0%
90 Day19.9%7.7%13.3%
1 Year56.4%55.0%23.2%21.7%6.0%3.7%
3 Year47.1%40.2%129.8%124.9%1.1%-6.9%
5 Year-0.8%-8.1%232.8%219.7%7.8%-6.8%

Price Volatility Vs. Market

How volatile is Getinge's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Getinge undervalued compared to its fair value and its price relative to the market?

32.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GTN (€20.42) is trading below our estimate of fair value (€30.37)

Significantly Below Fair Value: GTN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GTN is good value based on its PE Ratio (30.4x) compared to the DE Medical Equipment industry average (52.3x).

PE vs Market: GTN is poor value based on its PE Ratio (30.4x) compared to the German market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: GTN is poor value based on its PEG Ratio (6.7x)


Price to Book Ratio

PB vs Industry: GTN is good value based on its PB Ratio (2.7x) compared to the DE Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Getinge forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

4.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTN's forecast earnings growth (4.5% per year) is above the savings rate (0.2%).

Earnings vs Market: GTN's earnings (4.5% per year) are forecast to grow slower than the German market (23.4% per year).

High Growth Earnings: GTN's earnings are forecast to grow, but not significantly.

Revenue vs Market: GTN's revenue (2.2% per year) is forecast to grow slower than the German market (5.9% per year).

High Growth Revenue: GTN's revenue (2.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GTN's Return on Equity is forecast to be low in 3 years time (10.2%).


Next Steps

Past Performance

How has Getinge performed over the past 5 years?

-16.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GTN has high quality earnings.

Growing Profit Margin: GTN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: GTN's earnings have declined by 16.1% per year over the past 5 years.

Accelerating Growth: GTN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GTN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.9%).


Return on Equity

High ROE: GTN's Return on Equity (8.9%) is considered low.


Next Steps

Financial Health

How is Getinge's financial position?


Financial Position Analysis

Short Term Liabilities: GTN's short term assets (SEK18.9B) exceed its short term liabilities (SEK2.0B).

Long Term Liabilities: GTN's short term assets (SEK18.9B) do not cover its long term liabilities (SEK26.0B).


Debt to Equity History and Analysis

Debt Level: GTN's debt to equity ratio (56.6%) is considered high.

Reducing Debt: GTN's debt to equity ratio has reduced from 114.1% to 56.6% over the past 5 years.

Debt Coverage: GTN's debt is well covered by operating cash flow (45.1%).

Interest Coverage: GTN's interest payments on its debt are well covered by EBIT (10.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Getinge current dividend yield, its reliability and sustainability?

0.71%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GTN's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.25%).

High Dividend: GTN's dividend (0.71%) is low compared to the top 25% of dividend payers in the German market (3.83%).


Stability and Growth of Payments

Stable Dividend: GTN's dividend payments have been volatile in the past 10 years.

Growing Dividend: GTN's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (21.8%), GTN's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GTN's dividends in 3 years are forecast to be well covered by earnings (28.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Mattias Perjos (48 yo)

3.42yrs

Tenure

kr46,043,000

Compensation

Mr. Mattias Perjos has been the Chief Executive Officer and President at Getinge AB since March 27, 2017. Mr. Perjos serves as Chief Executive Officer at FlexLink Systems, Inc. Mr. Perjos has been the Dire ...


CEO Compensation Analysis

Compensation vs Market: Mattias's total compensation ($USD5.27M) is above average for companies of similar size in the German market ($USD3.70M).

Compensation vs Earnings: Mattias's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mattias Perjos
CEO, President & Director3.42yrskr46.04m0.013%
SEK 700.5k
Lars Sandström
Chief Financial Officer2.67yrsno data0.0048%
SEK 267.0k
Lars Mattsson
Head of Investor Relationsno datano datano data
Lena Hagman
Executive Vice President of Quality & Regulatory Compliance4.58yrsno data0.0013%
SEK 74.1k
Abraham Ronai
General Counselno datano datano data
Jeanette Carlsson
Executive Vice President of Communications & Brand Management3.17yrsno datano data
Magnus Lundbäck
Executive Vice President of Human Resources & Sustainability3.58yrsno data0.00037%
SEK 20.5k
Dieter Engel
Chief Technology Officer of Surgical Workflows4.58yrsno datano data
Carsten Blecker
Chief Commercial Officer2.67yrsno data0.00037%
SEK 20.5k
Jens Viebke
President of Acute Care Therapiesno datano data0.00040%
SEK 22.1k
Stéphane Roy
President of Surgical Workflows1.75yrsno data0.00092%
SEK 50.9k
Ralf Schmit
Corporate Head of Sustainabilityno datano datano data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: GTN's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mattias Perjos
CEO, President & Director3.42yrskr46.04m0.013%
SEK 700.5k
Johan Bygge
Independent Director13.33yrskr852.00k0.0044%
SEK 243.8k
Carl Bennet
Vice Chairman of Board0.58yrkr684.00k20.03%
SEK 1.1b
Malin Persson
Independent Director6.58yrskr684.00k0.0019%
SEK 107.3k
Johan Stern
Director16.58yrskr684.00k0.014%
SEK 751.4k
Johan Malmquist
Chairman1.33yrskr1.31m0.033%
SEK 1.8m
Cecilia Wennborg
Independent Director10.33yrskr722.00k0.0016%
SEK 91.2k
Barbro Fridén
Independent Director3.42yrskr684.00k0.00065%
SEK 35.9k
Rickard Karlsson
Employee Representative Director7.58yrsno datano data
Åke Larsson
Employee Representative Director0.17yrno datano data
Dan Frohm
Director3.42yrskr814.00k0.055%
SEK 3.0m
Sofia Hasselberg
Independent Director3.42yrskr722.00kno data

3.4yrs

Average Tenure

55.5yo

Average Age

Experienced Board: GTN's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Getinge AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Getinge AB
  • Ticker: GTN
  • Exchange: DB
  • Founded: 1904
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr57.143b
  • Listing Market Cap: kr5.529b
  • Shares outstanding: 272.37m
  • Website: https://www.getinge.com

Number of Employees


Location

  • Getinge AB
  • Lindholmspiren 7A
  • Gothenburg
  • Västra Götaland County
  • 417 56
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNGB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMay 1993
GETI BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMay 1993
GTNDB (Deutsche Boerse AG)YesClass B SharesDEEURMay 1993
0GZVLSE (London Stock Exchange)YesClass B SharesGBSEKMay 1993
GETIBSBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMay 1993
GNGB.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDOct 2008

Biography

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/02 21:22
End of Day Share Price2020/07/31 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.